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Abstract
Background: Enterovirus (EV) 71 is the main pathogen associated with hand, foot and mouth disease (HFMD)
or herpangina. Outbreaks of HFMD caused by EV71 infection are associated severe neurological disease and
high mortality rates in children. Several sporadic cases of EV71 infection occurred in the Republic of Korea
(ROK) in 2000, and EV71 infections were not reported thereafter until 2006. In this prospective study, we
report the epidemic and virologic characteristics of the EV71 endemic from 2007 to 2012 in the Republic
of Korea.
Methods: We analyzed characteristics of the EV71 infection-associated epidemic from collected specimens
and clinical information from 9987 patients with suspected EV infection from the National EV Surveillance
System in ROK. To identify the EV71 subgenotype, the homology of viral protein 1 sequences obtained
using reverse transcription polymerase chain reaction was compared with the sequences on other countries
available from GenBank database.
Results: EV71 was detected in 585 (16.7 %) specimens (cerebrospinal fluid, stool or rectal swabs, throat swabs
and blood) during study period and was most frequently observed during epidemic seasons in 2009–2012.
Major manifestations due to EV71 infection were HFMD (62.2 %) and HFMD with severe neurological complications
(28.4 %). Five deaths (0.9 %) due to EV71 infection occurred, with an increased mortality rate during the period after
2009. Most patients (476; 81.4 %) were less than 5 years of age. Analysis of the monthly distribution showed
that there was an obvious seasonal pattern to the epidemics, with infections appearing from June to August.
The major subgenotype of EV71 isolates circulating in ROK was the C4a strain, which has also appeared in
China, Japan and Vietnam.
Conclusions: This surveillance provided valuable data on the epidemic characteristics of EV71 infections in ROK
during a 6-year period. Our findings provide data to assist during future outbreaks of EV71 and associated acute
neurologic disease.
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Background
Human enterovirus (EV) 71 belongs to the family Picor-
naviridae, genus Enterovirus, which includes poliovi-
ruses, echoviruses, coxsackieviruses A and B and EV
types 68–70 [1]. EV71 can be classified into three geno-
types, A, B and C, based on phylogenetic tree analysis
using the nucleotide sequence of virus capsid protein
(VP) 1 [2]. EV71, as the main pathogen associated with
hand, foot and mouth disease (HFMD) or herpangina as-
sociated neurological and cardiac complications, may
lead to outbreaks of HFMD, which is associated with
high mortality rates in children.
EV71 was first described in 1974 after isolation from
patients in California in 1969 [3]. Since then, EV71 has
been isolated from various locations worldwide, includ-
ing the United States of America, Australia and Europe,
with circulation of different subgenotypes [4–6]. Strains
of B5 subtype have caused outbreaks in Asian countries,
including Malaysia, Singapore and Taiwan, since 1997
[7, 8]. Since 1998, EV71 infection rates have appeared to
increase, particularly for subgenotype C4 in China [9].
Moreover, in the late 1990s, in the Asia-Pacific region
frequent EV71-associated HFMD epidemics have oc-
curred, with high incidences of severe neurologic com-
plications and increased fatality rates [10–15].
From studies of EV71 infections, researchers have
found that the central nervous system (CNS) is likely the
target of the EV71 virus [16]. Since 2008, outbreaks of
EV71 infection associated with neurologic involvement,
i.e., HFMD with CNS complications, have been reported
in the Republic of Korea (ROK) [17, 18]. Moreover,
EV71 has emerged as an important target for the up-
coming era of poliomyelitis eradication [8]. In the ROK,
sporadic cases of EV71 infection occurred in 2000 [19];
however, death or severe effects of EV71 infection were
not reported until 2006. Therefore, in this study, we first
examined the epidemic and virologic characteristics of
the EV71 endemic from 2007 to 2012 in the ROK. We
analyzed the etiology of EV71-associated HFMD or her-
pangina and complications in ROK from 2007 to 2012




The Korea Centers for Disease Control and Prevention
(KCDC) National EV Surveillance System consists of
180 clinics managed by pediatric physicians (35 primary
clinics, 105 secondary hospitals and 40 tertiary hospitals
nationwide) and has monitored EV infections since
1993. Participating physicians collected specimens from
patients whose illnesses included HFMD, herpangina,
meningitis, encephalitis and sepsis, and documented pa-
tient age, date of specimen collection, symptoms and
suspected diagnosis. Analysis of the specimens, includ-
ing typing of relevant EV71 and phylogenetic analysis,
was carried out at the National Polio Laboratory of
KCDC.
Patients and clinical samples
Specimens and clinical information were collected from
patients suspected of having EV infection from 2007 to
2012. Participating clinics provided cerebrospinal fluid
(CSF), stool or rectal swabs, throat swabs and blood
samples from the patients. Information regarding age,
gender and manifestation was collected for all patient
samples, and samples were used to confirm presence of
EV71.
Detection of EV71 in clinical samples
Patient specimens were used for EV71 detection and
molecular typing. Viral RNA was extracted using
magnetic beads (GM-AUTOPREP Kit; Greenmate Co.,
Seoul, South Korea) according to the manufacturer’s
instructions, and the purified viral nucleic acid was
processed by using Freedom EVO (Tecan, Männedorf,
Switzerland). A highly conserved 5′ noncoding region
was the target of a previously described 196-bp region
[20]. To determine the EV genotype, conventional
reverse transcription polymerase chain reaction (RT-
PCR) was carried out for detection of VP1 using
primers designed in a previously study [21]. In the
ROK, cell culture and RT-PCR were used for identifi-
cation of EV strains from 1993 to 2004; after 2005,
detection of VP1 by RT-PCR was used to genotype
EV as a routine detection method, and real-time RT-
PCR detection of EV71 was used as the standard
detection method since 2008, providing more rapid
analysis [22]. The partial VP1 sequences of EV71 have
been deposited in GenBank with the accession num-




To analyze the genetic characteristics of EV71 cases, the
VP1 gene from EV71 isolates was examined by conven-
tional RT-PCR. VP1 partial sequences for the EV71 iso-
lates were compared with those of foreign strains.
Multiple sequence alignments with the respective refer-
ence strain sequences were carried out using DNAstar
Sequence Alignment Editor. MEGA software (version
4.0) was used for phylogenetic analysis. Phylogenetic
trees were constructed using the neighbor-joining
method (bootstrap resampling of 1000 replicates).
Sequence data from both strands were aligned and edi-
ted using MEGA.
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Results
The prevalence and epidemiological features of EV71
infections
From 2007 to 2012, we collected specimens and clinical
information from 9987 patients with suspected EV infec-
tions in the ROK. The annual outcomes of EV and EV71
from 2007 to 2012 are shown in Table 1. A total of 3502
(35 %) patients were confirmed as EV positive by labora-
tory analyses. EV71 infection was confirmed 585
(16.7 %) of EV-positive patients (Table1). In the ROK,
EV71 was detected for the first time in 2000 (12 cases),
and no cases were confirmed from 2001 to 2005 (data
not shown). In 2006, six cases were confirmed as EV71.
Since 2009, EV71 has been confirmed at a frequency
similar to those of other EV types (Table 1).
The overall age distribution of enrolled patients in-
fected with EV71 included neonates through patients
who were 37 years of age (data not shown). The mean
age was 3.57 ± 4.6 years, and median age was 3 years.
During this period, most patients were less than 15 years
of age (95.4 %); in particular, 476 (81.4 %) cases occurred
in young children less than 5 years age. Nine (1.6 %)
neonates (less than 1 month old) and 178 (30.3 %) chil-
dren less than 1 year of age acquired EV71 infections.
Among the study population, age was not listed for 16
(3.2 %) cases. Of the EV71 isolates, 339 were from males
and 235 were from females, giving a male-to-female
ratio of approximately 3:2 (data not shown). Information
regarding the sex of 11 patients was unavailable.
In this study, monthly distribution showed that EV71
infection followed an obvious seasonal pattern and
occurred during the short period from June to August in
2007–2012 (Fig. 1).
Clinical features of patients with EV71
The classification for clinical manifestations of EV71-
positive patients is described in Table 2. HFMD was the
major clinical sign (n = 364, 62.2 %). We found that 198
cases exhibited HFMD only, while 166 (28.4 %) cases ex-
hibited HFMD with CNS complications. The incidence
of EV71infection of the CNS accompanied by HFMD
was increased beginning in 2009 (no cases in 2008 and
26.0 % of patients in 2009). The other clinical symptoms
were aseptic meningitis (n = 136, 23.2 %), encephalitis or
meningoencephalitis without HFMD (n = 19, 3.2 %),
myocarditis (n = 2, 0.3 %), and sepsis (n = 13, 2.2 %). We
also received reports of death (n = 5, 1.1 % among 435
cases during 2009–2011) associated with EV71 infection
between 2009 and 2011 (two cases in 2009, two cases in
2010 and one case in 2011). Fatalities occurred due to
neurological complications. In 2009, two deaths caused
by EV71 infection occurred in female infants approxi-
mately 12 months of age who showed signs of encephal-
itis accompanied by HFMD. Additionally, in 2010, two
male infants died of EV71 infection at 10 and 13 months
of age. One patient showed signs of meningitis accompan-
ied by HFMD, while other patients suffered from lung
hemorrhage with HFMD in 2010. Another case of EV71
infection occurred in a 16-month-old infant with myocar-
ditis and meningitis accompanied by HFMD in 2011.
Sequence comparison and phylogenetic analysis of EV71
EV71 genetic groups can be classified into three distinct
clusters (A, B and C) with some temporal and regional
subclustering [7]. Based on this classification, all of the
isolates in the current study, with the exception of two
strains (HM443644-2009 typed as C1 and HM443663-
2009 typed as C5), belonged to subgenotype C4a (Fig. 2).
These strains (i.e., C4a) are common in China, Japan
and Vietnam [7].
Discussion
In this study, we examined the occurrence of EV71 in-
fection during the period from 2007 to 2012 according
to the National EV Surveillance System in the ROK. The
present study included clinical records of EV71-infected
patients and analysis of laboratory findings, including
determination of genetic differences between outbreaks
in the ROK and those in other countries. Moreover, in
this study, we found that EV71 infection exhibited a
seasonal trend based on epidemiological information for
EV71 infection and focused on EV71 infection as an
etiological risk factor associated with complications.
We found that this virus tended to infect younger in-
dividuals and caused more severe symptoms, including
death, in very young patients. EV71 infection, which was
the most frequently detected strain during the study
period, is associated with neurological complications
and, since 2009, has been responsible for most cases of
EV infection. Notably, EV71 was not detected at all
between 2001 and 2005, after 12 cases were reported
in 2000 [19].
Table 1 Prevalence of enterovirus71 and enterovirus in the
Republic of Korea from 2007 to 2012
Year No. samples No. (%) EV positive No. (%) EV71 Ranka
2007 691 132 (19.1) 22 (16.7) 3b
2008 1911 1010 (52.9) 2 (0.2) Out of rank 5c
2009 2765 869 (31.4) 127 (14.6) 1
2010 1445 557 (38.5) 190 (34.1) 1
2011 1812 593 (32.7) 118 (19.9) 1
2012 1363 341 (25.0) 126 (37.0) 1
Total 9987 3502 (35.1) 585 (16.7) -
EV enterovirus
aMost frequent ranking among human enterovirus genotype
bCoxsackie virus B2, Coxsakievirus A9 was rank1 and 2 in 2007
c.Included Echovirus30, Echovirus6, CoxsakievirusA10, CoxsakievirusB3,
CoxsakievirusB1 in rank 5
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EV71 induces HFMD or herpangina, which can exhibit
a severe clinical course accompanied by neurological
complications, leading to death in five cases. EV71 was
reported as a cause of HFMD, which is associated with a
high prevalence of acute neurologic disease [23]. Since
1997, multiple cases of EV71 infection have been shown
to be associated with severe aseptic meningitis and pul-
monary edema in the Asia-Pacific region, including
Taiwan, Malaysia, Singapore and Japan [12, 24–27].
Moreover, HFMD outbreaks in this region included the
ROK have been shown to be associated with EV71 infec-
tion and continue to pose an enormous threat to public
health due to the increased morbidity and mortality
rates associated with HFMD-related neurological
complications.
Based on phylogenetic analyses, the ROK isolates
belonged to a cluster of the subtype C4a and showed
high homology with isolates circulating in other
countries. EV71 often occurs in a cyclical pattern,
emerging every 2–3 years, in various countries [10].
Interestingly, a C4 virus has been the predominant
circulating strain in China since 1998, Taiwan since
2002 and Japan since 2003 [7, 8]. Thus, EV71 sub-
type C4 has become a predominant strain and has
been continuously circulating and causing epidemics
in neighboring countries and regions. Moreover, the
C4a subtype of EV71 was dominantly identified in
the ROK since 2009 and has been continuously
monitored for more than 4 years. Previous studies
have suggested that the EV71 cyclical pattern may
arise according to the proportion of herd immunity
among the susceptible population after a major out-
break [28, 29].
The clinical manifestations of EV71 infection were
consistent with results from previous studies and
showed that the majority of cases occurred in children
Fig. 1 Seasonal distribution of EV71 infection from 2007 to 2012 in the Republic of Korea. EV71, enterovirus 71
Table 2 Clinical manifestationsfromcases of enterovirus71 infection in Korea between 2007 and 2012
Clinical syndrome/Year 2007 2008 2009 2010 2011 2012 Total
n % n % n % N % N % n % n %
HFMD or herpangina 11 50.0 1 50.0 103 81.1 133 70.0 58 49.2 58 46.0 364 62.2
Without complication 11 50.0 1 50.0 70 55.1 70 36.8 10 8.5 36 28.6 198 33.8
With aseptic meningitis 33 26.0 63 33.2 42 35.6 18 14.3 156 26.7
With encephalitis or ME 6 5.1 3 2.4 9 1.5
With ADEM 1 0.8 1 0.2
Aseptic meningitis only 8 36.4 18 14.2 46 24.2 31 26.3 33 26.2 136 23.2
Encephalitis or ME only 2 1.6 6 3.2 7 5.9 4 3.2 19 3.2
Myocarditis 2 1.7 2 0.3
Sepsis 1 0.8 3 1.6 5 4.2 4 3.2 13 2.2
Othersa 3 13.6 1 50.0 3 2.4 2 1.1 15 12.7 27 21.4 51 8.7
Total 22 3.8 2 0.3 127 21.7 190 32.5 118 20.2 126 21.5 585 100.0
Death 2 1.6 2 1.1 1 0.8 5 0.9
HFMD hand-foot-mouth disease, ADEM acute disseminated encephalomyelitis, ME meningoencephalitis
aSymptoms such as fever, cold syndrome, abdominal pain, sore throat and manifestations of a suspected enterovirus infection
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less than 5 years of age, as has been observed in other
countries [30, 31]. Thus, infection with EV71 may
become serious public health concern, particularly for
children. Additionally, EV71 infections generally exhibit
an increased incidence in summer and early autumn
[30, 32]. As expected in temperate climates, the present
study revealed a seasonal pattern of distribution, with
transmission peaking in the summer and decreasing in
the period from autumn to spring. Few cases occurred
during the winter.
One limitation of this study was that only a subset of
VP1 sequences were used for phylogenetic studies.
Another study found that the results of VP1-based phylo-
genetic trees are not similar to those of complete genome-
based analyses [33]. Published data on EV epidemiology
revealed that recombination between EV71 genotypes B
or C and other types of coxsakieviruses occurred in
Asian-Pacific countries [8, 9, 11, 15, 34–36]. For EV, gen-
etic recombination has been reported to result in the
emergence of viruses with altered pathogenic potential
[36]. Unfortunately, in this study, we were unable to
examine the occurrence of homologous recombination.
Further studies are needed to analyze EV71 dynamic
mutations and genetic variation in the EV71 subtype
through the analysis of full genome sequences.
Conclusions
The present study indicated that EV71 was prevalent
among EV-positive patients in the ROK during a recent 6-
year period. Because of the impact of EV71 infection on
public health, HFMD was designated as a nationally notifi-
able communicable disease in 2009, allowing for more
comprehensive surveillance programs in the ROK. The
surveillance reported in this study provides valuable data
on the phylogenetic patterns and clinical manifestations
associated with EV71 infection. Our findings also provide
relevant information for future development of preventive
vaccines and treatment plans. In addition, the information
on EV71 infection reported in this study may provide
important insights into the general outcomes of EV71
infection and associated acute neurologic disease.
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